May 20, 2024

Cell Therapy Manufacturing Market Size, Share, Report by 2033

The global cell therapy manufacturing market size was estimated at USD 4.20 billion in 2023 and is projected to reach around USD 16.89 billion by 2033, growing at a CAGR of 14.93% from 2024 to 2033.

Key Points

  • The North America cell therapy manufacturing market size accounted for USD 1.85 billion in 2023 and is expected to attain around USD 7.43 billion by 2033.
  • North America led the market with the major revenue share of 44% in 2023.
  • Asia Pacific is expected to witness the fastest growth during the forecast period.
  • By therapy type, the autologous cell therapy segment has held the biggest revenue share of 59% in 2023.
  • By therapy type, the allogenic cell therapy segment is projected to be the fastest-growing segment over the forecast period.
  • By technology type, the somatic cell technology segment held the largest share of the market in 2023.
  • By technology type, the 3D technology segment is expected to grow at the fastest rate during the projected period.
  • By source, the IPSC (induced pluripotent stem cell) segment dominated the market in 2023.
  • By source, the bone marrow segment is the second largest segment in the global market.
  • By application, the oncology segment has contributed the largest revenue share of 35% in 2023.
  • By application, the neurological segment is projected to show fastest growth during the forecast period.

Cell Therapy Manufacturing Market Size 2024 to 2033

The cell therapy manufacturing market encompasses the processes and technologies involved in the production of cell-based therapies, which are designed to treat various diseases and conditions by harnessing the therapeutic properties of living cells. This market is rapidly evolving due to the increasing demand for personalized and regenerative medicines that offer innovative treatment options beyond traditional pharmaceuticals.

Get a Sample: https://www.precedenceresearch.com/sample/4283

Growth Factors

Several key factors are driving the growth of the cell therapy manufacturing market. One significant factor is the expanding pipeline of cell therapy products entering clinical trials and gaining regulatory approval. Advances in biotechnology and cell biology have also facilitated the development of scalable manufacturing processes, enabling efficient production of cell-based therapies at commercial scales. Additionally, growing investments from biotechnology companies and government initiatives to support cell therapy research further contribute to market growth.

Region Insights

The cell therapy manufacturing market exhibits regional variations influenced by factors such as regulatory frameworks, infrastructure, and market demand. North America and Europe are prominent regions for cell therapy manufacturing, characterized by well-established biopharmaceutical industries and supportive regulatory environments. Emerging markets in Asia-Pacific, particularly China and South Korea, are also gaining traction due to investments in biotechnology infrastructure and a rising focus on regenerative medicine.

Cell Therapy Manufacturing Market Scope

Report Coverage Details
Growth Rate from 2024 to 2033 CAGR of 14.93%
Cell Therapy Manufacturing Market Size in 2023 USD 4.20 Billion
Cell Therapy Manufacturing Market Size in 2024 USD 4.83 Billion
Cell Therapy Manufacturing Market Size by 2033 USD 16.89 Billion
Largest Market North America
Base Year 2023
Forecast Period 2024 to 2033
Segments Covered By Therapy Type, By Technology Type, By Source, and By Application
Regions Covered North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa

 

Cell Therapy Manufacturing Market Dynamics

Drivers

Key drivers shaping the cell therapy manufacturing market include advancements in cell culture technologies, automation, and process optimization. The increasing prevalence of chronic diseases and aging populations worldwide is fueling demand for innovative therapies, driving investments in cell therapy manufacturing infrastructure. Furthermore, collaborations between academic institutions, biotechnology firms, and contract manufacturing organizations (CMOs) are accelerating the translation of research into commercial cell therapy products.

Opportunities

Numerous opportunities exist within the cell therapy manufacturing market, particularly in the development of novel manufacturing platforms that enhance scalability, reduce production costs, and ensure consistent product quality. The expansion of global regulatory frameworks to support cell therapy approvals presents opportunities for market entry and product commercialization. Moreover, the integration of digital technologies such as data analytics and machine learning into manufacturing processes can optimize efficiency and accelerate product development.

Challenges

Despite its promising outlook, the cell therapy manufacturing market faces several challenges. One major challenge is the complexity of manufacturing processes involving living cells, which require specialized infrastructure and stringent quality control measures. Scalability remains a hurdle, with the need to transition from small-scale research and development to large-scale commercial production. Additionally, regulatory compliance and standardization of manufacturing practices across different geographies pose challenges to market expansion and product accessibility. Addressing these challenges will be crucial for sustaining growth and ensuring the widespread adoption of cell-based therapies.

Read Aso: Brazil Industrial Absorbent Market Size, Share, Report by 2033

Cell Therapy Manufacturing Market Recent Developments

  • In March 2024, Cellars announced the completion of the first Cell Shuttle, an automated, cGMP-compliant cell therapy manufacturing platform to support the global demand for cell therapies while reducing the cost of manufacturing and process failure rates.
  • In March 2023, Cell One Partners and the Center for Breakthrough Medicines (CBM) entered into a strategic collaboration aimed at accelerating the development and commercialization of cell and gene therapies. This collaboration brings together the expertise and resources of both organizations to drive innovation and advance the field of regenerative medicine.
  • In September 2022, the Cell Therapy Manufacturing Center (CTMC) and Ori Bio collaborated to expedite the process development, commercialization, and clinical integration of cell therapies. This partnership aimed to enhance the advancement of cell-based treatments and bring them to patients more efficiently.

Cell Therapy Manufacturing Market Companies

  • Merck KGaA
  • Thermo Fisher Scientific
  • Catalent, Inc
  • Bio-Techne
  • Cytiva
  • Lonza
  • The Discovery Labs
  • Novartis AG
  • Bristol-Myers Squibb Company
  • Gilead Sciences, Inc.

Segments Covered in the Report

By Therapy Type

  • Allogenic Cell Therapy
  • Autologous Cell Therapy

By Technology Type

  • Somatic Cell Technology
  • Cell Immortalization Technology
  • Viral Vector Technology
  • Genome Editing Technology
  • Cell Plasticity Technology
  • 3D Technology

By Source

  • IPSC (Induced Pluripotent Stem Cell)
  • Bone Marrow
  • Umbilical Cord
  • Adipose Tissues
  • Neural Stem

By Application

  • Musculoskeletal
  • Cardiovascular
  • Gastrointestinal
  • Neurological
  • Oncology
  • Dermatology
  • Others

By Geography

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • Middle East & Africa

Contact Us:

Mr. Alex

Sales Manager

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Web: https://www.precedenceresearch.com

Blog: https://www.expresswebwire.com/

Blog: https://www.uswebwire.com/

Blog: https://www.dailytechbulletin.com/

Blog: https://www.autoindustrybulletin.com/

Leave a Reply

Your email address will not be published. Required fields are marked *